Dapagliflozin: first SGLT2 inhibitor for type 2 diabetes
نویسندگان
چکیده
منابع مشابه
SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
BACKGROUND Because of the progressive nature of the disease, most patients with type 2 diabetes mellitus eventually require multiple treatments to achieve glycaemic targets. The majority of available therapies are insulin dependent, aiming to decrease insulin resistance and increase insulin secretion. Sodium glucose co-transporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents, limit ...
متن کاملEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
Although antidiabetic agents have been developed to target one or more of the core defects of type 2 diabetes mellitus (T2DM), many patients do not achieve glycemic goals. Inhibition of the sodium-glucose cotransporter 2 (SGLT2) induces glycosuria, reduces glucose toxicity and improves insulin sensitivity and β-cell function. As the mechanism of action of SGLT2 inhibitors is different from othe...
متن کاملDapagliflozin (Farxiga) for Type 2 Diabetes Mellitus.
Because dapagliflozin has been shown to induce glycosuria, patients should be warned about the most common clinical sequelae of osmotic diuresis, hypotension, and hypoglycemia. Systolic blood pressure typically decreases by 2.3 to 5.6 mm Hg. However, hypotension is relatively uncommon (number needed to harm [NNH] = 337) and mainly affects older adults, patients on loop diuretics, and those with...
متن کاملDapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Type 2 diabetes mellitus (T2DM) is a growing worldwide epidemic. Patients face lifelong therapy to control hyperglycemia and prevent the associated complications. There are many medications, with varying mechanisms, available for the treatment of T2DM, but almost all target the declining insulin sensitivity and secretion that are associated with disease progression. Medications with such insuli...
متن کاملCorrection: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
[This corrects the article DOI: 10.1371/journal.pone.0158810.].
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Prescriber
سال: 2013
ISSN: 0959-6682
DOI: 10.1002/psb.1076